Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Phase 3

Active, not recruiting

• Conditions: Parkinson's Disease (PD)
• Interventions: Drug: ABBV-951

• Registration Number: NCT04750226
• Lead Sponsor: AbbVie

Brief Summary

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated.

ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia.

Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-02-10
• Study First Submitted QC: 2021-02-10
• Study First Posted: 2021-02-11
• Study Start: 2021-02-18
• Status Verified: 2025-08
• Last Update Submitted: 2025-08-07
• Last Update Posted: 2025-08-12
• Primary Completion: 2026-04
• Study Completion: 2026-04-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 118

Inclusion Criteria

• Completion of the parent study, Study M15-736 or Study M20-339.

Exclusion Criteria

• Participant considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ABBV-951	ABBV-951	Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period.

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Impulsive-Compulsive Disorders and related behaviors as assessed in Parkinson's Disease- Rating Scale (QUIP-RS)	Up To Week 96	The QUIP-RS is a brief, self-completed or rater-administered rating scale to assess the severity of symptoms of impulse control disorders (ICDs) and related behaviors reported to occur in PD. The QUIP-RS uses a 5-point Likert scale that requires individuals to rate the severity of each symptom based on its frequency.
Percentage of Participants with Adverse Event (AEs)	Up to Week 96	An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An SAE is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.
Percentage of Participants with AEs of Special Interest (AESIs)	Up to Week 96	AESIs are defined as AEs from "special situations," such as accidental or intentional overdose, medication error, occupational or accidental exposure, off-label use, drug abuse, drug misuse, or drug withdrawal, all which must be reported whether associated with an AE or not.
Percentage Of Participants With Letter Grade Equal To Or Higher Than D On The Infusion Site Evaluation Scale	Up To Week 96	The Infusion Site Evaluation Scale will be used to assess infusion sites. Infusion Site Evaluation Scale is an A to G letter grade scale, used to assess irritation at the infusion site area (A being "no finding" to G being "Small petechial erosions and/or scabs").
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements like Systolic and Diastolic Blood Pressure will be Assessed	Up to Week 96	Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.
Change From Baseline in Electrocardiograms (ECGs)	Up to Week 96	12-lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration.
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed.	Up to Week 96	Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed..
Percentage Of Participants With Numeric Grade Equal To Or Higher Than 5 On The Infusion Site Evaluation Scale	Up To Week 96	The Infusion Site Evaluation Scale will be used to assess infusion sites. Infusion Site Evaluation Scale is an eight-point numeric scale used to assess irritation at the infusion site area (0 being "no evidence of irritation" and 7 being "strong reaction spreading beyond the test site").
Change From Baseline in Suicidality as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)	Up To Week 96	C-SSRS is a systematically administered instrument designed to assess suicidal behavior and ideation, track and assess all suicidal events, and assess the lethality of attempts. Any participant who has suicidal behavior or suicidal ideation with plan since the last C-SSRS completed, will be evaluated immediately by the investigator.
Change From Baseline in Cognitive Impairment as Assessed by the Mini-Mental State Examination (MMSE)	Up To Week 96	Cognitive impairment is assessed by the Mini-Mental State Examination (MMSE). MMSE is a brief 30-point questionnaire, administered by a trained rater, that provides a quantitative measure of cognitive status in adults and is used widely to screen for cognitive impairment and to estimate the severity of cognitive impairment at a given point in time, to follow the course of changes in a patient over time, and to document response to treatment.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Motor Experiences of Daily Living	Up To Week 96	Motor experiences of daily living is assessed by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II. The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.
Change From Baseline in PD Symptoms as Assessed by the MDS-UPDRS Tool Parts I-III	Up To Week 96	The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.
Percentage Of Participants With Early Morning "Off" Assessed by the PD Diary as Percentage of Participants with early morning "Off" Upon Waking Up	Up To Week 96	Early morning "Off" status is assessed by the PD Diary as percentage of participants with early morning "Off" upon waking up.
Change From Baseline in Average Normalized "On" Time as Assessed by the Parkinson's Disease (PD) Diary	Up To Week 96	Change in "On" time without dyskinesia or with non-troublesome dyskinesia as assessed by the PD diary.
Change From Baseline in Average Daily Normalized "Off" Time as Assessed by the PD Diary	Up To Week 96	Change in average daily normalized "Off" Time (Hours) is assessed based on PD Diary.
Change From Baseline in PD Symptoms as Assessed by the MDS-UPDRS Tool Part I	Up To Week 96	The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.
Change From Baseline in PD Symptoms as Assessed by the MDS-UPDRS Tool Part III	Up To Week 96	The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.
Change From Baseline in PD Symptoms as Assessed by the MDS-UPDRS Tool Part IV	Up To Week 96	The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.
Change From Baseline in Sleep Symptoms	Up To Week 96	Sleep symptoms are assessed by the Parkinson's Disease Sleep Scale-2 (PDSS-2). The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep.
Change From Baseline in Quality Of Life as Assessed by the PD Questionnaire-39 item (PDQ-39)	Up To Week 96	Quality of life is assessed by the PD Questionnaire-39 item (PDQ-39). PDQ-39 is a disease-specific instrument designed to measure aspects of health that are relevant to participants with PD, and which may not be included in general health status questionnaires. Each item is scored on a 5-point scale.
Change From Baseline in Health-related Quality of Life as Assessed by EQ-5D-5L	Up To Week 96	Health-related quality of life is assessed by EQ-5D-5L. EQ-5D-5L is a standardized instrument that consists of 2 parts: the EQ-5D descriptive system and the EQ visual analogue-scale (EQ-VAS).

Trial Locations

Locations (52)

University of Alabama at Birmingham - Main /ID# 217814; 🇺🇸 Birmingham, Alabama, United States

University of South Alabama /ID# 218467; 🇺🇸 Mobile, Alabama, United States

Xenoscience, Inc /ID# 222515; 🇺🇸 Phoenix, Arizona, United States

Muhammad Ali Parkinson Center /ID# 218609; 🇺🇸 Phoenix, Arizona, United States

Movement Disorders Center of Arizona /ID# 218471; 🇺🇸 Scottsdale, Arizona, United States

Neuro Pain Medical Center /ID# 217720; 🇺🇸 Fresno, California, United States

Loma Linda University Medical /ID# 217724; 🇺🇸 Loma Linda, California, United States

University of California, Los Angeles /ID# 218460; 🇺🇸 Los Angeles, California, United States

SC3 Research Group - Pasadena /ID# 223018; 🇺🇸 Pasadena, California, United States

University of California, San /ID# 218595; 🇺🇸 San Diego, California, United States

Scroll for more (42 remaining)